Natriuretic peptides in APE prognosis: primary results of the meta-analysis
| Outcome | No of studies | References | Proportion of events (95% CI) | Pooled OR (95% CI) | Homogeneity | |
| p Value | I2 (%) | |||||
| All-cause mortality | 16 | 4, 15–22, 24, 27–32 | (+): 62/491, 12.6% (9.6% to 15.5%) | 6.2 (3.0 to 12.7) | 0.96 | 0.0 |
| (−): 5/433, 1.1% (0.1% to 2.1%) | ||||||
| APE-related mortality | 14 | 4, 15–18, 21, 24, 27–31, 34, 35 | (+): 40/378, 10.6% (7.9% to 14.1%) | 5.0 (2.2 to 11.5) | 0.97 | 0.0 |
| (−): 3/298, 1.0% (0.3% to 2.9%) | ||||||
| Serious adverse events | 9 | 15, 19, 21, 22, 24, 26, 28, 32, 35 | (+): 115/416, 27.6% (23.4% to 32.0%) | 6.7 (3.9 to 11.6) | 0.83 | 0.0 |
| (−): 17/319, 5.3% (2.8% to 7.7%) | ||||||
| Right ventricular dysfunction | 14 | 4, 15–17, 20–26, 28, 31, 32 | (+): 352/487, 72.3% (68.3% to 76.3%) | 24.2 (11.4 to 51.3) | 0.001 | 61.1 |
| (−): 71/412, 17.2% (13.6% to 20.9%) | ||||||
APE, acute pulmonary embolism; CI, confidence interval; OR, odds ratio.
(+) indicates the proportion of patients with the outcome of interest among those with positive natriuretic peptides; (−) indicates the proportion of patients with the outcome of interest among those with negative natriuretic peptides.